Skip to main content

Table 4 Correlation analysis of the factors associated with urinary glucose on day 7 of treatment with SGLT2 inhibitors

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

 

Urinary glucose

p value

MBG

0.414*

0.050

SD

−0.209

0.337

CV

−0.305

0.157

Time at >140 mg/dL

0.468*

0.024

Time at <70 mg/dL

−0.228

0.298

Time at 70–140 mg/dL

−0.470*

0.023

MAGE

0.135

0.539

LAGE

−0.381

0.073

M value

0.303

0.159

MPPGE

−0.093

0.673

Max

0.012

0.955

Min

0.474*

0.022

  1. Data are results of Pearson correlation analysis of variables with normal distribution (MBG, CV and Max) and Spearman rank correlation for variables with skewed distribution
  2. IRI immunoreactive insulin, HbA1c glycated hemoglobin, CPR C peptide immunoreactivity, eGFR estimated glomerular filtration rate, CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  3. * p < 0.05